First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm

(2020) Elodie Bôle-Richard et al.   LEUKEMIA

Engineering Chimeric Antigen Receptor T cells Against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer

(2020) Ching-Yao Yang et al.   Molecular Therapy-Oncolytics

Three types of HLA-G+ extravillous trophoblasts that have distinct immune regulatory properties

(2020) Henrieta Papuchova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HLA-G Neo-Expression on Tumors

(2020) Maria Loustau et al.   Frontiers in Immunology

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth

(2020) Le Qin et al.   Biomarker Research

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

A safe and potent anti-CD19 CAR T cell therapy

(2019) Zhitao Ying et al.   NATURE MEDICINE

CD8+PD-1–ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G

(2019) Clement Dumont et al.   Cancer Immunology Research

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

Structural and Functional Basis for LILRB Immune Checkpoint Receptor Recognition of HLA-G Isoforms

(2019) Kimiko Kuroki et al.   JOURNAL OF IMMUNOLOGY

Immune-related Adverse Events Associated With Checkpoint Inhibition in the Setting of CAR T Cell Therapy: A Case Series

(2019) Swetha Kambhampati et al.   Clinical Lymphoma Myeloma & Leukemia

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL

(2018) John Rossi et al.   BLOOD

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G

(2018) Christian Spurny et al.   Oncotarget

In vivo fate and activity of second versus third-generation D19-specific CAR-T cells in B-cell non-Hodgkin lymphomas

(2018) Carlos A. Ramos et al.   MOLECULAR THERAPY

Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8+ T cells

(2018) Francois Desgrandchamps et al.   Oncotarget

Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges

(2018) Aifen Lin et al.   Frontiers in Immunology

Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients

(2017) Diana Tronik-Le Roux et al.   Molecular Oncology

FDA approves first CAR T therapy

(2017) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

PRIME time at the EMA

(2017) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

HLA-G: At the Interface of Maternal–Fetal Tolerance

(2017) Leonardo M.R. Ferreira et al.   TRENDS IN IMMUNOLOGY

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities

(2017) An-Liang Xia et al.   Oncotarget

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?

(2017) Sylvain Simon et al.   OncoImmunology

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

(2016) Gideon Gross et al.   Annual Review of Pharmacology and Toxicology

HLA-G promotes myeloid-derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4

(2016) Natascha Köstlin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G

(2016) Sareetha Kailayangiri et al.   OncoImmunology

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy

(2016) Vita Golubovskaya et al.   Cancers

HLA-G expression levels influence the tolerogenic activity of human DC-10

(2015) G. Amodio et al.   HAEMATOLOGICA

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

(2015) Roy L. Maute et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HLA-G expression levels influence the tolerogenic activity of human DC-10

(2015) G. Amodio et al.   HAEMATOLOGICA

HLA-G Orchestrates the Early Interaction of Human Trophoblasts with the Maternal Niche

(2015) Silvia Gregori et al.   Frontiers in Immunology

Human CD4+HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo

(2014) Susann Pankratz et al.   FASEB JOURNAL

In vivoevidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance

(2014) Laure Loumagne et al.   INTERNATIONAL JOURNAL OF CANCER

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

HLA-dependent tumour development: a role for tumour associate macrophages?

(2013) Maddalena Marchesi et al.   Journal of Translational Medicine

The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting

(2012) S Kailayangiri et al.   BRITISH JOURNAL OF CANCER

Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors

(2012) Kiave-Yune HoWangYin et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The tolerogenic interplay(s) among HLA-G, myeloid APCs, and regulatory cells

(2011) E. D. Carosella et al.   BLOOD

Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17

(2011) S. Agaugue et al.   BLOOD

HLA-G Level on Monocytoid Dendritic Cells Correlates With Regulatory T-Cell Foxp3 Expression in Liver Transplant Tolerance

(2011) Antonino Castellaneta et al.   TRANSPLANTATION

Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway

(2010) S. Gregori et al.   BLOOD

T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible

(2009) Yu-Hwa Huang et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Beyond the increasing complexity of the immunomodulatory HLA-G molecule

(2008) E. D. Carosella et al.   BLOOD

HLA-G: from biology to clinical benefits

(2008) Edgardo D. Carosella et al.   TRENDS IN IMMUNOLOGY

Phenotypic and functional differentiation of KG-1 into dendritic-like cells

(2007) I. Teobald et al.   IMMUNOBIOLOGY